-
Je něco špatně v tomto záznamu ?
Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells
J. Kovář, M. Ehrlichová, B. Šmejkalová, .I Zanardi, I. Ojima, I. Gut
Jazyk angličtina Země Řecko
Typ dokumentu srovnávací studie, práce podpořená grantem, Research Support, N.I.H., Extramural
Grantová podpora
NR9426
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- antibiotika antitumorózní farmakologie MeSH
- antitumorózní látky fytogenní farmakologie MeSH
- apoptóza účinky léků MeSH
- buněčné dělení účinky léků MeSH
- chemorezistence MeSH
- doxorubicin farmakologie MeSH
- fluorescenční mikroskopie MeSH
- G1 fáze účinky léků MeSH
- G2 fáze účinky léků MeSH
- kaspasa 2 metabolismus MeSH
- kaspasa 3 metabolismus MeSH
- kaspasa 8 metabolismus MeSH
- kaspasa 9 metabolismus MeSH
- lidé MeSH
- mikrotubuly účinky léků MeSH
- nádorové buněčné linie MeSH
- nádory prsu farmakoterapie metabolismus patologie MeSH
- paclitaxel farmakologie MeSH
- proliferace buněk účinky léků MeSH
- taxoidy farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- srovnávací studie MeSH
BACKGROUND: In this study, the effect of novel taxane SB-T-1216 and paclitaxel on sensitive MDA-MB-435 and resistant NCI/ADR-RES human breast cancer cells was compared. MATERIALS AND METHODS: Cell growth and survival were evaluated after 96-hour incubation with tested concentrations of taxanes. The effect on the formation of microtubule bundles was assessed employing fluorescence microscopy and on the cell cycle employing flow cytometric analysis. The activity of caspases was assessed employing commercial colorimetric kits. RESULTS: The IC(50) (concentration resulting in 50% of living cells in comparison with the control) of SB-T-1216 in sensitive cells was 0.6 nM versus 1 nM for paclitaxel. However, the IC(50) of SB-T-1216 in resistant cells was 1.8 nM versus 300 nM for paclitaxel. Both SB-T-1216 and paclitaxel at death-inducing concentrations induced the formation of microtubule bundles in sensitive as well as resistant cells. Cell death induced in sensitive and resistant cells by paclitaxel was associated with the accumulation of cells in the G(2)/M phase. On the contrary, cell death induced by SB-T-1216 took place without the accumulation of cells in the G(2)/M phase but with a decreased number of G(1) cells and the accumulation of hypodiploid cells. Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells. CONCLUSION: Cell death induced by both paclitaxel and novel taxane SB-T-1216 in breast cancer cells is associated with caspase activation and with the formation of interphase microtubule bundles. Novel taxane SB-T-1216, but not paclitaxel, seems to be capable of inducing cell death without the accumulation of cells in the G(2)/M phase.
- 000
- 03827naa 2200529 a 4500
- 001
- bmc11019516
- 003
- CZ-PrNML
- 005
- 20221005141408.0
- 008
- 110714s2009 gr e eng||
- 009
- AR
- 035 __
- $a (PubMed)19661300
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Kovář, Jan, $d 1952- $7 jn20040114001
- 245 10
- $a Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells / $c J. Kovář, M. Ehrlichová, B. Šmejkalová, .I Zanardi, I. Ojima, I. Gut
- 314 __
- $a Department of Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Ruska 87, 10000 Prague 10, Czech Republic. jan.kovar@lf3.cuni.cz
- 520 9_
- $a BACKGROUND: In this study, the effect of novel taxane SB-T-1216 and paclitaxel on sensitive MDA-MB-435 and resistant NCI/ADR-RES human breast cancer cells was compared. MATERIALS AND METHODS: Cell growth and survival were evaluated after 96-hour incubation with tested concentrations of taxanes. The effect on the formation of microtubule bundles was assessed employing fluorescence microscopy and on the cell cycle employing flow cytometric analysis. The activity of caspases was assessed employing commercial colorimetric kits. RESULTS: The IC(50) (concentration resulting in 50% of living cells in comparison with the control) of SB-T-1216 in sensitive cells was 0.6 nM versus 1 nM for paclitaxel. However, the IC(50) of SB-T-1216 in resistant cells was 1.8 nM versus 300 nM for paclitaxel. Both SB-T-1216 and paclitaxel at death-inducing concentrations induced the formation of microtubule bundles in sensitive as well as resistant cells. Cell death induced in sensitive and resistant cells by paclitaxel was associated with the accumulation of cells in the G(2)/M phase. On the contrary, cell death induced by SB-T-1216 took place without the accumulation of cells in the G(2)/M phase but with a decreased number of G(1) cells and the accumulation of hypodiploid cells. Both SB-T-1216 and paclitaxel activated caspase-3, caspase-9, caspase-2 and caspase-8 in sensitive as well as resistant cells. CONCLUSION: Cell death induced by both paclitaxel and novel taxane SB-T-1216 in breast cancer cells is associated with caspase activation and with the formation of interphase microtubule bundles. Novel taxane SB-T-1216, but not paclitaxel, seems to be capable of inducing cell death without the accumulation of cells in the G(2)/M phase.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a antibiotika antitumorózní $x farmakologie $7 D000903
- 650 _2
- $a antitumorózní látky fytogenní $x farmakologie $7 D000972
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
- 650 _2
- $a kaspasa 2 $x metabolismus $7 D053143
- 650 _2
- $a kaspasa 3 $x metabolismus $7 D053148
- 650 _2
- $a kaspasa 8 $x metabolismus $7 D053181
- 650 _2
- $a kaspasa 9 $x metabolismus $7 D053453
- 650 _2
- $a buněčné dělení $x účinky léků $7 D002455
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a doxorubicin $x farmakologie $7 D004317
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a G1 fáze $x účinky léků $7 D016193
- 650 _2
- $a G2 fáze $x účinky léků $7 D016195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fluorescenční mikroskopie $7 D008856
- 650 _2
- $a mikrotubuly $x účinky léků $7 D008870
- 650 _2
- $a paclitaxel $x farmakologie $7 D017239
- 650 _2
- $a taxoidy $x farmakologie $7 D043823
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Ehrlichová, Marie $7 xx0067467
- 700 1_
- $a Hořejší, Barbora $7 xx0140329
- 700 1_
- $a Zanardi, Ilaria
- 700 1_
- $a Ojima, Iwao
- 700 1_
- $a Gut, Ivan, $d 1936- $7 xx0060370
- 773 0_
- $t Anticancer Research $w MED00000478 $g Roč. 29, č. 8 (2009), s. 2951-2960
- 856 41
- $u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838769/ $y plný text volně přístupný
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110715114105 $b ABA008
- 991 __
- $a 20221005141404 $b ABA008
- 999 __
- $a ok $b bmc $g 864455 $s 729393
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00000478 $b 29 $c 8 $d 2951-2960 $m Anticancer research $n Anticancer Res
- GRA __
- $a NR9426 $p MZ0
- LZP __
- $a 2011-3B09/Bjvme